



Edgar Filing: TRANSGENOMIC INC - Form 8-K

mutations associated with response to therapy in lung cancer. A copy of the press release is filed herewith as Item 9.01 and is incorporated herein by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Press Release, dated February 1, 2006, announcing the use of the Company's WAVE System and Surveyor Nuclease to detect mutations associated with response to therapy in lung cancer.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRANSGENOMIC, INC.

By /s/ Mitchell L. Murphy  
-----  
Mitchell L. Murphy  
VP, Secretary & Treasurer

February 1, 2006

3